Imports account for nearly five times Bosnia’s domestic pharmaceutical turnover

Bosnia’s pharmaceutical market reaches KM1.18 billion

Pharmaceutical turnover in Bosnia and Herzegovina reached KM1,181,345,058.43 in 2025, according to a report prepared by the country’s Agency for Medicinal Products and Medical Devices and reported by Bljesak.info. The total combines imports of foreign medicines with sales reported by domestic pharmaceutical manufacturers.

Imported medicines accounted for KM978,883,756.43, while turnover generated by domestic producers was KM202,461,302.00. Based on those figures, imports were about 4.8 times the value of domestic production and represented approximately 82.9% of the market’s financial turnover. Domestic manufacturers supplied the remaining 17.1% by value.

The figures show the scale of Bosnia and Herzegovina’s reliance on foreign pharmaceutical supply. For domestic manufacturers, the difference also indicates the size of the market currently served by international suppliers, although the agency’s financial data do not reveal whether imported and locally produced medicines compete within the same therapeutic categories.

Cancer and immune-system medicines lead spending

Antineoplastic and immunomodulating medicines generated the largest turnover among the main categories, at KM242.5 million. These products, used to treat malignant diseases and regulate the immune system, represented 20.53% of total pharmaceutical turnover in 2025.

Medicines for the alimentary tract and metabolism ranked second, with turnover of KM185.3 million and a 15.69% share. Cardiovascular medicines followed at KM172 million, equivalent to 14.56% of the total. Medicines affecting blood and blood-forming organs generated KM117 million, or 9.90%, while nervous-system medicines reached KM116.9 million, also reported as 9.90%.

Together, these five broad categories accounted for most of the market’s value. Their ranking points to particularly high financial demand in oncology, immune-system treatment, metabolic disease and cardiovascular care. However, the published figures do not separate imported turnover from domestic turnover within each category, so they cannot establish which areas offer the greatest practical substitution opportunity for local producers.

Therapeutic groups highlight chronic-disease demand

At the level of individual therapeutic groups, antineoplastic medicines recorded the highest turnover. Other leading groups included antihyperglycemic medicines used in diabetes treatment; products acting on the renin-angiotensin system for hypertension and other cardiovascular conditions; antithrombotic agents; and antibacterial medicines for systemic use.

The mix places treatments for cancer, diabetes, cardiovascular disease and infections among the most financially significant parts of Bosnia and Herzegovina’s pharmaceutical market. It is relevant to manufacturers assessing product portfolios, distributors planning inventories and international suppliers evaluating demand, but the report does not provide company-level data, product volumes, prices or countries of origin.

Turnover does not measure patient consumption

The agency stressed that the report measures pharmaceutical turnover in financial terms. It does not measure actual medicine consumption by the population or disclose the number of packages dispensed. The values therefore reflect market revenue rather than treatment volumes and may be affected by differences in medicine prices across therapeutic categories.

This distinction is especially important when comparing high-value specialist products with more widely used lower-priced medicines. The data demonstrate a large financial dependence on imports, but additional information on package volumes, active ingredients, procurement prices and manufacturing capacity would be required to assess supply security or the realistic scope for expanding domestic production.